Dr. Pat Soon-Shiong

So the Thymus produces T cells. IL-15 is a T cell growth factor. When the Thymus is removed, there is a 2x higher chance of dying earlier of all causes according to this report. These findings are consistent with the JAMA paper that shows when ALC is less than 1,500 (low T cells) longevity is decreased with increased mortality risk from all causes. The data is consistent: IL-15 is a T cell growth factor and they called T cells because of the T in Thymus. And IL-15 was ranked #1 by NCI and FDA to "cure" cancer as far back as 2007. Now this report links the Thymus (which produces T cells) to longevity - consistent with the JAMA report that 52 million Americans suffer from low T cells, called lymphopenia. IL-15 to treat cancer, enable longevity and to overcome sepsis - Immunotherapy 2.0. Stay tuned. Are the dots connecting that ALC matters? JAMA Zidar 2019: "Association of Lymphopenia With Risk of Mortality Among Adults in the US General Population" jamanetwork.com/journals/jaman… WaPo Gift Link: "The body's most mysterious organ may play a key role in longevity and cancer. What to know about the incredible shrinking thymus"

As far back as 2019, Richard Pazdur, then head of OCE at FDA, recognized the importance of lymphocyte count in progression free survival and overall survival in lung cancer. I just discovered this paper today, just as I recently discovered the 2007 NCI workshop report showing the importance of T cell growth factor. He concludes that "baseline LDH level and dNLR are important prognostic biomarkers irrespective of treatment modality for patients with mNSCLC" meaning that whether the patient receives radiation, chemo, or checkpoint inhibitors, the level of lymphocyte count (ALC) is the critical biomarker for outcomes regardless of treatment modality. The Saudi FDA recognized this immediately and on that basis approved Anktiva for the treatment of 2nd line lung cancer who relapsed following standard of care. Pazdur further states "As further prospective clinical trial information is collected, the role of the LIPI score can be better defined." Stay tuned.

The FDA is on the HUNT for promising therapies.

From ⁦@latimes⁩ latimes.com/world-nation/l…

Everyone should listen to this. An intelligent mind created the universe and life. God created not only life but the NK cell by the Cambrian Age when new forms of life leading to mankind evolved in an explosion of biology so that our exquisite mammalian forms of life could survive. 450 million years ago an intelligent design for NK cells to exist and 50 million years ago in evolving single chain antibodies... all to protect form cancer and infection. The fine tuning of life at 10 to the 90th power... everything is balanced in order for us to have life!!! As I said, NK cells was an invention of God... we need to finally acknowledge this cells value to humanity. Science matters. Stephen Meyer, John Lennox, and James Tour: Three Scientists on the Origins of Everything youtube.com/watch?v=JW9gcj…

#4 Triple Negative Breast Cancer, Metastatic Disease Coming soon at ESMO, a study by Dr. Aditya Bardia at UCLA and Dr. Hope Rugo at City of Hope - two world class opinion leaders in breast cancer who present results in May 2026 in Berlin at ESMO-Breast, entitled "Pre-treatment neutrophil-to-lymphocyte ratio and impact on immunotherapy efficacy in patients with metastatic triple-negative breast cancer (mTNBC)". Data is embargoed until then. Stay tuned, ALC matters. High NLR ratio means a high neutrophil with a low lymphocyte count - a bad sign for outcome. Stay tuned.

The evidence generated by UCLA is compelling. This presentation entitled, "Sustained lymphopenia during neoadjuvant chemo-immunotherapy is associated with worse outcomes in early triple-negative breast cancer" was presented at ASCO-IO (Feb 2026). #3 ASCO-IO (Feb 2026): Early Stage Triple Negative Breast Cancer (TNBC) In a 372 patient study, the data shows that only 15% of patients with early stage TNBC have a pathological complete response (pCR) when the ALC is less than 1,000 cells while 82% of patients with NK and T cells (ALC greater than 1,000 cells) have a complete response after therapy. This difference is stark and significant (p=0.034). Dr Bardia states:”Sustained lymphopenia and the development of relative lymphopenia during neoadjuvant chemo-immunotherapy may reflect impaired anti-tumor immune responses in patients with early-stage TNBC, highlighting need for intervention therapeutics in this setting“ Conclusion: Treatment-induced lymphopenia can impact anti-tumor immune responses and disease outcomes in patients with early-stage TNBC, highlighting the need for therapeutic interventions in this setting aacrjournals.org/cancerimmunolr…

“China is now eating our lunch.” RFK Jr. warns the U.S. is losing its edge to China in medical research and drug development. “They got more drugs approved last year.” “They went from running 3% of clinical trials to running 30%.” “We are losing scientists, we’re losing our IPs, we’re losing the best researchers.” “We’re going to lose our biosecurity.” “We are fast-tracking approvals now in our country at record levels.”

#2: The Beat Goes On (April 21, 2026) - Early Stage 1, 2, & 3 Breast Cancer: In a breaking news presentation at #AACR26 today, Dr. Aditya Bardia at UCLA that Post-COVID lymphopenia results in a 2.46-fold increased risk of distant recurrence occurs in patients with lymphopenia even in early stage breast cancer (Stage 1, 2, 3) with a p=0.009. This finding was highly significant and in contrast, patients without lymphopenia did not suffer a recurrence. An important demonstration that low NK and T cells affect the progression of the disease even in patients in remission. aacrjournals.org/cancerres/arti…

Here we go with the drumbeat of evidence of how lymphopenia results in poorer prognosis in breast cancer, regardless of type and regardless of stage by Dr. Aditya Bardia, a renowned UCLA breast cancer oncologist. #1 Dec 2025: Early stage TRIPLE NEGATIVE BREAST CANCER at San Antonio Breast Cancer Symposium (SABCS): A study demonstrating that lymphopenia is associated with statistically LOWER pathological complete response (pCR) rates in patients with early-stage triple negative breast cancer (TNBC) treated with neoadjuvant chemo-immunotherapy. News tomorrow at @AACR on Stage 1, 2, and 3 breast cancer. aacrjournals.org/clincancerres/…

We are treating a patient under an FDA authorized Single patient IND with this issue. This is a clinical study and not an approved indication but we are finding what is known as T cell exhaustion. More clinical trials are being planned with this interesting finding that the potential exists to reverse it. The trials will explore this hypothesis.

The independent research by a world renowned breast cancer oncologist at UCLA, Dr Aditya Barda, breaks news today at AACR that consistently shows regardless of the stage of BREAST CANCER, that post Covid lymphopenia results in poorer prognosis, poorer response to treatment and even 2x higher recurrence when patients are in remission. The relationship of low NK and low T cells to breast cancer ( and frankly all cancers ) is so clear. Will share his data that he presented at major breast cancer conferences and now at AACR next. Very compelling

So glad to see that awareness of this IL15 superagonist is beginning…yet it had awareness through evolution 450 million years ago, then again in2007, almost 20 years ago by NCI/ NIH ….. and now 2026. Science enlightenment takes time !

News will break tomorrow. Evidence of an INCREASE OF OVER 2TIMES THE RISK of distant recurrence of breast cancer( in patients in remission ) with lymphopenia ( low TCells and low NK cells). So ALC matters in patients in remission with early stage (1 to 3 ) breast cancer . An easy test to monitor lymphopenia and to address this increased risk.

FDA is moving proactively to advance potential therapies to address America’s mental health crisis. It’s time for new approaches.

The President can make huge advances in transforming the health of Americans.

Building human bridges across the globe in our war against cancer. Sharing our knowledge is the greatest policy for combined effort to change the paradigm on a global basis for the good of all patients. More to come.

Excited to bring Global esports to LA…the sports capital !!! LATMG emerging. Health and sports to bring the world together.

Great meetings today. Transforming cancer globally at scale. @ClevelandClinic